<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC5360A4-17EF-4970-9A81-98DFBA9EFF84"><gtr:id>BC5360A4-17EF-4970-9A81-98DFBA9EFF84</gtr:id><gtr:name>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC5360A4-17EF-4970-9A81-98DFBA9EFF84"><gtr:id>BC5360A4-17EF-4970-9A81-98DFBA9EFF84</gtr:id><gtr:name>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/239EDB30-D26B-4003-8090-63D2899A310C"><gtr:id>239EDB30-D26B-4003-8090-63D2899A310C</gtr:id><gtr:firstName>Edel</gtr:firstName><gtr:surname>O'Toole</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C1B59EE0-2FB9-4458-A7B2-08B1D23D5681"><gtr:id>C1B59EE0-2FB9-4458-A7B2-08B1D23D5681</gtr:id><gtr:firstName>Judith</gtr:firstName><gtr:surname>Breuer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700814"><gtr:id>27DE9D72-A144-42CB-958A-AAA0066F6945</gtr:id><gtr:title>Reverse genetics to map determinants of Varicella zoster Oka vaccine attenuation and virulence.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700814</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The aim of this proposal is to investigate, using whole genome sequencing, reverse genetics and in vitro assays of replication and function,the viral determinants of Oka varicella-zoster vaccine strain attenuation and virulence. The Oka vaccine is licensed in the USA and other countries for immunisation of children to prevent chickenpox. Although safe and effective, the vaccine can cause life-threatening infection if given to patients with impaired cell-mediated immunity. Since these patients are at greatest risk of complications and death from chicknpox, newer safer vaccines are still needed. There is no good animal model which adequately replicates VZV propagation and virulence in vivo. This has hampered attempts to link vaccine mutations with clinical phenotype. We have shown, using a statistical genetics approach, that despite attnuation of the Oka vaccine for replication in skin, some vaccine variants within the vaccine mix are rash-forming. In a separate study, we have identified an altered batch of pre-licensure vOka vaccine, which caused an unusually high number of rashes. Finally, we have obtained a vOka virus which transmitted from a child with vaccine-rash, to cause fully virulent chickenpox. These viruses provide a valuable resource with which to examine the genetic determinants of Oka vaccine attenuation and VZV pathogenicity. To exploit this unique clinical material, we propose developing PCR-based genome sequencing. This will make use of the small amounts of viral DNA available and will establish a proof of concept applicable to other viral genomes. We will use techniques established in our lab to reconstruct viruses of interest and to assay their replication in models of differentiated epithelia. The location of over 1/3 of vaccine mutations in the gene coding for the major viral transactivating protein IE62, together with the association of changes in IE62 with rash formation implies, an important role in viral virulence. Functional differences between IE62 molecules using currently available reporter assays are not well detected. We now propose to use time lapse confocal microscopy of fluorescent-tagged molecules to investigate IE62 distibution and recruitment of celluar proteins in early infection . Similar experiments using the Herpes simplex virus (HSV) homologue of IE62 suggest that altered proteins are distributed differently early in infection and may function less efficiently. 
 This project will allow mapping of the vaccine mutations associated with clinical virulence and the development of in vitro assays of viral function and replication. The results will inform studies to improve vaccine safety.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>913293</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>whole viral genome sequencing</gtr:description><gtr:id>4ADE675C-2E5F-4331-AB73-20B43CA7D2FB</gtr:id><gtr:impact>IP on targeted enrichment for pathogen sequencing</gtr:impact><gtr:outcomeId>Xw9td1Rerqg-1</gtr:outcomeId><gtr:partnerContribution>Joint IP
development of methods 
Joint grant applications 
Joint papers in press</gtr:partnerContribution><gtr:piContribution>Developed targeted enrichment for pathogen sequencing
contributed to bioinformatic tools</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Infection and Immunity</gtr:department><gtr:description>? MRC: Suppressing Inflammation to Enhance Antigen-Specific Immunity in Older Humans Using p38 MAPkinase Inhibitors and Vitamin D,</gtr:description><gtr:id>F3195675-A2B5-436D-A312-9BB203EF6808</gtr:id><gtr:impact>none from me</gtr:impact><gtr:outcomeId>589461de31d7d9.83419960-1</gtr:outcomeId><gtr:partnerContribution>Arne Akbar is PI. he is examining the immunology of reduced vaccine responses to TB and VZV in the elderly.</gtr:partnerContribution><gtr:piContribution>to examine the effect of ageing on replication of the live vaccine in skin and whether this can partially explain reduced zoster vaccine immunogenicity in elderly</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>persis amrolia</gtr:description><gtr:id>DF0627FF-CB8C-48E6-BBF0-CC229CB2F893</gtr:id><gtr:impact>collection of samples from patients with high EBV and low EBV . these will be analysed to see if t cell control is different</gtr:impact><gtr:outcomeId>5800b1e17803c1.15642067-1</gtr:outcomeId><gtr:partnerContribution>provided expertise in t cell assays againse ebv</gtr:partnerContribution><gtr:piContribution>sequencing EBV genomes from patients with ptld</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>school viist</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>DC449736-DB93-44E1-A45F-228F0B0FABDF</gtr:id><gtr:impact>small group of 3 pupils as part of work experience prgramme. all considering science as a carreer. at least two have decided to apply to do science at Uni

see above</gtr:impact><gtr:outcomeId>JBKCzJrik9b</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>news night measlescommentary</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>62113212-C199-4673-85AA-061C989A0A3B</gtr:id><gtr:impact>helped to reduce anxiety about measles outbreaks

in undatedwith further requests fo interviews</gtr:impact><gtr:outcomeId>Rw6VTGcrY9A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of the third age</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>6AB66FE5-C7B8-45DE-8CB8-EA3F3A6C8126</gtr:id><gtr:impact>lecture on vzv and the developments for shingles

asked to return and give a follow up lecture</gtr:impact><gtr:outcomeId>pVDt1yJrReo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LBC talk radio</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>601FE2D3-B996-4EC2-80A0-1F9FC4E9E1A9</gtr:id><gtr:impact>allayed fears a obout measles vaccine

asked to do moreinterviews</gtr:impact><gtr:outcomeId>QnVapsAPkVq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>work experience supervision</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>46F561FB-E099-49DE-8A2C-C8DB4AB9BBE5</gtr:id><gtr:impact>groups of 1-3 students shadowed myself and my lab and undertook small research projects

very positive feedback from schools and pupils. encouraged several to choose science at university</gtr:impact><gtr:outcomeId>i4LmnxWnfyM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A cluster randomised controlled trial of a behavioural change package to prevent hand dermatitis in nurses working in the National Health Service</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>Dr I Madan Cost Centre 651125</gtr:fundingRef><gtr:id>7DC38ECA-DE69-40BF-88B7-DF46043191CD</gtr:id><gtr:outcomeId>eQNaUKqbg3J0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Pathseek Pathogens. Automated Next generation sequencing for diagnostic microbiology</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>304875</gtr:fundingRef><gtr:id>49B3006C-832E-4929-9DB5-B42A8200CEAE</gtr:id><gtr:outcomeId>Tm1frLyiUzg</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32535</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Impact s/Ship F. Wegner - Genomic studies of the impact of host/virus interaction in EBV infection using massively parallel high throughput sequencing</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Agilent Technologies</gtr:fundingOrg><gtr:fundingRef>3809903</gtr:fundingRef><gtr:id>D39C8D33-B051-4506-8019-4F74CA8C87D0</gtr:id><gtr:outcomeId>545cda4310a225.15729031</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centre for Molecular Virology</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0900950</gtr:fundingRef><gtr:id>698B8E54-5FBD-4CDD-83F1-8114BE307F1D</gtr:id><gtr:outcomeId>rKGT6BzvDun0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>bioinformatic tools for design of baits for targeted enrichment for pathogen sequencing</gtr:description><gtr:grantRef>G0700814</gtr:grantRef><gtr:id>ACFC38A1-5445-42C7-9FBF-634C29504CB8</gtr:id><gtr:impact>allows automated design of good baits for pathogen sequencing to enable adaptation for clinical use</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>UhKNEc5zUNf</gtr:outcomeId><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>tools for bait selection for viral genome sequencing</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>adaptation of targeted enrichment methods to sequencing of pathogens for diagnostic purposes</gtr:description><gtr:grantRef>G0700814</gtr:grantRef><gtr:id>A43457F5-03EB-4EA6-B4F0-B5D7C1ECD50F</gtr:id><gtr:impact>enables sequencing of pathogens directly from clinical material for associaton studies</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>sjVETPCqmwm</gtr:outcomeId><gtr:patentId>Insufficient Information</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>targeted enricment for pathogen sequencing</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Review of VZV nomenclature</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>769218DB-30C4-429E-81BC-7BFA96CDB48C</gtr:id><gtr:outcomeId>MavtvS78ASc</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chickenpox Guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2E1A17D8-B476-4546-AAB9-C9F6B7D4CD58</gtr:id><gtr:outcomeId>icbRV55LiBn</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of JCVI</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>347A41BB-E9DE-4A46-A5CB-4633E6C11F12</gtr:id><gtr:outcomeId>iMWAdJ2A9N5</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>common vzv nomenclature allows standardised surveillance of vaccine and wild type in post vaccine era. Now commonly adopted around the world</gtr:description><gtr:id>D1756672-C9A5-44BC-8F7B-CD572D8D542B</gtr:id><gtr:impact>Identification and standardisation of vaccine wild type recombinants</gtr:impact><gtr:outcomeId>WgLB4eFmPvf</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>standardised nomenclature for VZV genotypes</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>reagents to allow highly automated whole pathogen sequencing directly from clinical material for identification, resistance testing and molecular epidemiological studies</gtr:description><gtr:id>80484B8F-1BE4-4313-A42C-18749E151C7A</gtr:id><gtr:impact>has the potential to be a disruptive technology for microbiology technology</gtr:impact><gtr:outcomeId>Zso1pF29Xhg</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>whole pathogen genome sequencing</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>together with centres in the USA and Canada, we have established a standardised nomenclature for circulating strains of VZV. this has simplified publications and led to standardised methods for surveillance in vaccinated and unvaccinated populations</gtr:description><gtr:id>8966C9A9-DD6F-4741-A3DF-AC07E8A837FA</gtr:id><gtr:impact>Established common nomenclature usage for surveillance of vaccine strains. this has allowed public health bodies to standardise surveillance. One important outcome hasbeen the first identification of recombinant vaccine -wildtype viruses and comparision of these in different countries</gtr:impact><gtr:outcomeId>cSjTEYCho1i</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>standardised nomenclature for Varicella zoster virus stains</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>developed sureselect material for automated high throughput viral and other pathogen genome sequencing</gtr:description><gtr:id>F8558A53-9708-474C-AB3F-336846683FD8</gtr:id><gtr:impact>the methodology will make possible highly automated hight throughput viral genome sequencing for research and diagnosis</gtr:impact><gtr:outcomeId>GqJwRmpN5zX</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>targeted enrichment reagetns for whole dna viral genome sequencing</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C1171D82-AEFE-4E11-8B87-3D7CC65B4E30</gtr:id><gtr:title>Varicella zoster immune status in children treated for acute leukemia.</gtr:title><gtr:parentPublicationTitle>Pediatric blood &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26411df307dff7c30b56b6849f764e3d"><gtr:id>26411df307dff7c30b56b6849f764e3d</gtr:id><gtr:otherNames>Patel SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1545-5009</gtr:issn><gtr:outcomeId>544e7021649253.02376167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51B51790-8BB9-4468-ABFE-4DFD294F806F</gtr:id><gtr:title>Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1810b8703bb427d7da0643038ba59f43"><gtr:id>1810b8703bb427d7da0643038ba59f43</gtr:id><gtr:otherNames>Breuer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>544e6e686dac85.38054857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C72DB221-9F09-4D8A-9C93-D815982A5996</gtr:id><gtr:title>Household size is critical to varicella-zoster virus transmission in the tropics despite lower viral infectivity.</gtr:title><gtr:parentPublicationTitle>Epidemics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45473b1e4d4ef03d654e535b38732449"><gtr:id>45473b1e4d4ef03d654e535b38732449</gtr:id><gtr:otherNames>Nichols RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1878-0067</gtr:issn><gtr:outcomeId>rpLVhJdfmaE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40DC114F-F6E2-423C-8B94-60982FDB189A</gtr:id><gtr:title>Varicella-zoster viruses associated with post-herpetic neuralgia induce sodium current density increases in the ND7-23 Nav-1.8 neuroblastoma cell line.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/822dbffe60501f8c0e0e5efd59cbbf26"><gtr:id>822dbffe60501f8c0e0e5efd59cbbf26</gtr:id><gtr:otherNames>Kennedy PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544fb788bdb1a4.56432783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>318DF402-32E6-4306-90EB-7E3585E254B8</gtr:id><gtr:title>Specific capture and whole-genome sequencing of viruses from clinical samples.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03f50fdda9533c73c407c979b78d57e2"><gtr:id>03f50fdda9533c73c407c979b78d57e2</gtr:id><gtr:otherNames>Depledge DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13754_24_22125625</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A52130F7-9941-4C1E-9A7C-40C08D5B03EA</gtr:id><gtr:title>Evolution of cocirculating varicella-zoster virus genotypes during a chickenpox outbreak in Guinea-Bissau.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03f50fdda9533c73c407c979b78d57e2"><gtr:id>03f50fdda9533c73c407c979b78d57e2</gtr:id><gtr:otherNames>Depledge DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>doi_55f9849846e9bb88</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9979EBB4-474B-4C5F-BDA1-4ECA981AEACF</gtr:id><gtr:title>Chickenpox.</gtr:title><gtr:parentPublicationTitle>BMJ clinical evidence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1810b8703bb427d7da0643038ba59f43"><gtr:id>1810b8703bb427d7da0643038ba59f43</gtr:id><gtr:otherNames>Breuer J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-3846</gtr:issn><gtr:outcomeId>bwitA4ADLLp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24F81FFD-EE20-4A60-9FAE-B78AC3AD6E79</gtr:id><gtr:title>Assessment of transcriptomal analysis of Varicella-Zoster-virus gene expression in patients with and without post-herpetic neuralgia.</gtr:title><gtr:parentPublicationTitle>Virus genes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29e22048eff5e9af61d9da811878a6f0"><gtr:id>29e22048eff5e9af61d9da811878a6f0</gtr:id><gtr:otherNames>Ashrafi GH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0920-8569</gtr:issn><gtr:outcomeId>AnBypWVsrwQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C057961-825A-42C4-A726-39C3E44C2DAA</gtr:id><gtr:title>Debilitating clinical disease in a wild-born captive western lowland gorilla (Gorilla gorilla gorilla) co-infected with varicella zoster virus (VZV) and simian T-lymphotropic virus (STLV).</gtr:title><gtr:parentPublicationTitle>Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74fda91915eaf9b3b3f5f81db07cb478"><gtr:id>74fda91915eaf9b3b3f5f81db07cb478</gtr:id><gtr:otherNames>Masters N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1042-7260</gtr:issn><gtr:outcomeId>tLmAUyHoYX3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FFE0C4C-FC86-4E3A-9D8F-56CD994CA82C</gtr:id><gtr:title>Viral population analysis and minority-variant detection using short read next-generation sequencing.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d5303563010bfcdfe7d2f4a0d49d5c5"><gtr:id>9d5303563010bfcdfe7d2f4a0d49d5c5</gtr:id><gtr:otherNames>Watson SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>544fb7d5334fd6.25258759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A4F0837-5C09-44A0-9F45-2113F03ECE1C</gtr:id><gtr:title>Diffuse gallium-67 uptake in radiation pneumonitis.</gtr:title><gtr:parentPublicationTitle>Clinical nuclear medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4852c477c6aee3a53e3fd827ba8fd2f1"><gtr:id>4852c477c6aee3a53e3fd827ba8fd2f1</gtr:id><gtr:otherNames>Kataoka M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1990-01-01</gtr:date><gtr:issn>0363-9762</gtr:issn><gtr:outcomeId>pm_13754_254_2171844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7997B01D-3268-465D-9C5C-5E09FFF81641</gtr:id><gtr:title>Varicella zoster-specific CD4+Foxp3+ T cells accumulate after cutaneous antigen challenge in humans.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05d303595cecc95b47227c65d510287e"><gtr:id>05d303595cecc95b47227c65d510287e</gtr:id><gtr:otherNames>Vukmanovic-Stejic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_13754_24_23284056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7651DD20-DD86-4D89-BAFB-1466CCBE5CF7</gtr:id><gtr:title>Rates of vaccine evolution show strong effects of latency: implications for varicella zoster virus epidemiology.</gtr:title><gtr:parentPublicationTitle>Molecular biology and evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/464a69d208034edf889526a6f84cdb83"><gtr:id>464a69d208034edf889526a6f84cdb83</gtr:id><gtr:otherNames>Weinert LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0737-4038</gtr:issn><gtr:outcomeId>doi_55f9849846e053de</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4167281E-C100-4E2A-B789-29BDEB4A5F2E</gtr:id><gtr:title>Recombination of Globally Circulating Varicella-Zoster Virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b0e7d10e14cea420026b681663aa285"><gtr:id>7b0e7d10e14cea420026b681663aa285</gtr:id><gtr:otherNames>Norberg P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5675e3802dc33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>440D7550-305F-4BEA-9862-E7AFB18B97F0</gtr:id><gtr:title>Varicella postexposure prophylaxis in children with cancer: urgent need for a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1310a49d2095ad8f052c87095fac8e03"><gtr:id>1310a49d2095ad8f052c87095fac8e03</gtr:id><gtr:otherNames>Bate J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>pm_13754_24_22875905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35BC843D-D4B5-4E10-B1DA-907084D48493</gtr:id><gtr:title>Next-generation whole genome sequencing identifies the direction of norovirus transmission in linked patients.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c18528a81eb674069f4bfa80db10e10c"><gtr:id>c18528a81eb674069f4bfa80db10e10c</gtr:id><gtr:otherNames>Kundu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>544fb5de35fca8.03109979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53D0AF84-E53D-4E63-A523-183A43299797</gtr:id><gtr:title>Molecular studies of the Oka varicella vaccine.</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1a36b92200ae53de4ccff98ee0c23e9"><gtr:id>a1a36b92200ae53de4ccff98ee0c23e9</gtr:id><gtr:otherNames>Quinlivan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>XQk2AhCPQma</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FA774C7-E315-47AB-B8C0-30F2CCB67370</gtr:id><gtr:title>Clinical and molecular aspects of the live attenuated Oka varicella vaccine.</gtr:title><gtr:parentPublicationTitle>Reviews in medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1a36b92200ae53de4ccff98ee0c23e9"><gtr:id>a1a36b92200ae53de4ccff98ee0c23e9</gtr:id><gtr:otherNames>Quinlivan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1052-9276</gtr:issn><gtr:outcomeId>544e7089564907.12085089</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62AC1569-3A15-40DA-BFD6-A7DF13704E24</gtr:id><gtr:title>Mode of virus rescue determines the acquisition of VHS mutations in VP22-negative herpes simplex virus 1.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a487439957a8a457771f1264aa85442"><gtr:id>0a487439957a8a457771f1264aa85442</gtr:id><gtr:otherNames>Ebert K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>544fb733288393.68751663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD9893B2-1F38-4F4B-8E0C-455597A5723E</gtr:id><gtr:title>PEPtalk: postexposure prophylaxis against varicella in children with cancer.</gtr:title><gtr:parentPublicationTitle>Archives of disease in childhood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1310a49d2095ad8f052c87095fac8e03"><gtr:id>1310a49d2095ad8f052c87095fac8e03</gtr:id><gtr:otherNames>Bate J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9888</gtr:issn><gtr:outcomeId>kPfjhoRgRAG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3836F751-A29A-4978-B24A-8CECAFCCFA3F</gtr:id><gtr:title>Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e3b62786ad96e49cf906145414ca83c"><gtr:id>0e3b62786ad96e49cf906145414ca83c</gtr:id><gtr:otherNames>Weissenborn S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn><gtr:outcomeId>pm_13754_24_21792749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F45E9C2F-8479-483A-9600-4B6CEBD8EE72</gtr:id><gtr:title>Actinic varicella vaccine rash.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d305d30f2252848124080402ee6f8a1"><gtr:id>9d305d30f2252848124080402ee6f8a1</gtr:id><gtr:otherNames>Theodoridou K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn><gtr:outcomeId>pm_13754_24_21768921</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>549E2A91-1073-4C55-BB24-E4CD4A1EA2FF</gtr:id><gtr:title>Population diversity in batches of the varicella Oka vaccine.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d40ff938ba82c4aaea8a02b20aec1672"><gtr:id>d40ff938ba82c4aaea8a02b20aec1672</gtr:id><gtr:otherNames>Kanda RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>QG8vdK1oVT7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73D284C4-761A-4E4B-9AB7-BB3748EB9BBC</gtr:id><gtr:title>Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans.</gtr:title><gtr:parentPublicationTitle>Molecular biology and evolution</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03f50fdda9533c73c407c979b78d57e2"><gtr:id>03f50fdda9533c73c407c979b78d57e2</gtr:id><gtr:otherNames>Depledge DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0737-4038</gtr:issn><gtr:outcomeId>544fb5829a8239.96655570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D844C106-8FF9-4FAC-9FEF-FD06C3A24D2B</gtr:id><gtr:title>Subclinical VZV reactivation in immunocompetent children hospitalized in the ICU associated with prolonged fever duration.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6dc82100ecdddb89db9970c8da3a40ea"><gtr:id>6dc82100ecdddb89db9970c8da3a40ea</gtr:id><gtr:otherNames>Papaevangelou V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn><gtr:outcomeId>544fb8085c5107.79968664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79D19460-0210-4544-B41E-D8BF56EB3655</gtr:id><gtr:title>Factors associated with the seroprevalence of 26 cutaneous and two genital human papillomavirus types in organ transplant patients.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbe1d3b8a3eb8d461fe876a712738215"><gtr:id>bbe1d3b8a3eb8d461fe876a712738215</gtr:id><gtr:otherNames>Sampogna F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_13754_24_21900419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E151A7D-748D-49E0-A677-A30B6EFC54D3</gtr:id><gtr:title>Comparison of a commercial Varicella Zoster glycoprotein IgG enzyme immunoassay with a reference time resolved fluorescence immunoassay (VZV TRFIA) for measuring VZV IgG in sera from pregnant women, sera sent for confirmatory testing and pre and post vOka vaccination sera from healthcare workers.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6ac51d6e3619b71a00b561cb486c7fd"><gtr:id>c6ac51d6e3619b71a00b561cb486c7fd</gtr:id><gtr:otherNames>Maple PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn><gtr:outcomeId>pm_13754_24_22261123</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>264014B2-D51E-46BA-A0DC-7EF768B28DBD</gtr:id><gtr:title>Molecular diagnostics for gonorrhoea: implications for antimicrobial resistance and the threat of untreatable gonorrhoea.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c11cf96ca656857cba2ccd41c26bcf52"><gtr:id>c11cf96ca656857cba2ccd41c26bcf52</gtr:id><gtr:otherNames>Low N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>544fb4df3c5fc3.90593544</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5DAD300-449D-4E18-84A4-C9F726E63FC9</gtr:id><gtr:title>Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e04f6f825267e4c2e6800b0460ec0239"><gtr:id>e04f6f825267e4c2e6800b0460ec0239</gtr:id><gtr:otherNames>Hiwarkar P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>544fb87420a871.21050097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>052D8F2B-4FD5-42B9-8B37-BAFE0570615A</gtr:id><gtr:title>Genome Sequence of Human Herpesvirus 7 Strain UCL-1.</gtr:title><gtr:parentPublicationTitle>Genome announcements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/445e89510add42a0b7afe91dfd55d3ee"><gtr:id>445e89510add42a0b7afe91dfd55d3ee</gtr:id><gtr:otherNames>Donaldson CD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_13754_24_24115547</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D57A827C-FC40-498A-A374-FAA1CD666AC6</gtr:id><gtr:title>Herpes simplex virus and varicella zoster virus: recent advances in therapy.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bbea2fb84533f4ee5436e47de413890"><gtr:id>6bbea2fb84533f4ee5436e47de413890</gtr:id><gtr:otherNames>De SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>56dd9f785ec5b8.60957817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A6D60CB-87A5-489A-A3DE-BE0FD49509CD</gtr:id><gtr:title>Use of oral fluid to examine the molecular epidemiology of varicella zoster virus in the United Kingdom and continental Europe.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1a36b92200ae53de4ccff98ee0c23e9"><gtr:id>a1a36b92200ae53de4ccff98ee0c23e9</gtr:id><gtr:otherNames>Quinlivan M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>544fb8ad2f5e64.88996532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8DF7A98-8030-40CB-BBD0-B3072B67F555</gtr:id><gtr:title>RNA-seq analysis of host and viral gene expression highlights interaction between varicella zoster virus and keratinocyte differentiation.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f960dc64663392005f3fbcba53da956"><gtr:id>9f960dc64663392005f3fbcba53da956</gtr:id><gtr:otherNames>Jones M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>544fb544829439.37550972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>099C63AD-55EC-413E-AC49-F8DC34EA288B</gtr:id><gtr:title>Varicella vaccines.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef0e3245c1296cece5f434ba32bc407c"><gtr:id>ef0e3245c1296cece5f434ba32bc407c</gtr:id><gtr:otherNames>Flatt A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>pm_13754_24_22859715</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700814</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>